Tenax Therapeutics, Inc. (TENX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Tenax Therapeutics, Inc. (TENX) Healthcare & Pipeline Overview

Tenax Therapeutics, Inc. is a specialty pharmaceutical company developing and commercializing therapies for cardiovascular and pulmonary diseases. Their pipeline focuses on pulmonary hypertension treatments, including TNX-103, TNX-102 (levosimendan), and TNX-201 (imatinib), positioning them in a niche segment of the biotechnology sector.

What Is the Investment Thesis for TENX?

Tenax Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing treatments for pulmonary hypertension and related conditions addresses a significant unmet medical need. Key value drivers include the successful completion of clinical trials for TNX-103, TNX-102 (levosimendan), and TNX-201 (imatinib), leading to potential FDA approval and commercialization. The company's small size and limited resources present challenges, but successful drug development could result in substantial returns. The current market capitalization of $46.4M reflects the speculative nature of the investment, with potential upside dependent on positive clinical trial outcomes and regulatory approvals. Upcoming clinical trial results will be critical catalysts for the stock. However, potential setbacks in clinical trials or regulatory hurdles represent significant risks.

Based on FMP financials and quantitative analysis

TENX Key Highlights

Tenax Therapeutics focuses on cardiovascular and pulmonary diseases, a market with significant unmet needs.

• TNX-102 (levosimendan) has completed Phase II clinical trials, showing promise for treating pulmonary hypertension associated with heart failure with preserved ejection fraction.
• TNX-201 (imatinib) is a tyrosine kinase inhibitor being developed for pulmonary arterial hypertension, representing a novel approach to treatment.
• The company's small size (4 employees) allows for agility but also presents resource constraints.
• Tenax Therapeutics operates in the United States and Canada, targeting specific patient populations with limited treatment options.

Who Are TENX's Competitors?

TENX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TENX's Key Strengths?

Focus on cardiovascular and pulmonary diseases with unmet needs.

• Pipeline includes TNX-103, TNX-102 (levosimendan), and TNX-201 (imatinib).
• Completed Phase II clinical trials for TNX-102 (levosimendan).
• Experienced management team with expertise in drug development.

What Are TENX's Weaknesses?

Small company with limited resources (4 employees).

• Reliance on successful clinical trial outcomes and regulatory approvals.
• Limited commercialization experience.
• High cash burn rate.

What Could Drive TENX Stock Higher?

TENX catalyst: Clinical trial results for TNX-103 in pulmonary hypertension associated with heart failure with preserved ejection fraction.

• Clinical trial results for TNX-201 (imatinib) in pulmonary arterial hypertension.
• Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
• Regulatory submissions and approvals for pipeline products.

What Are the Key Risks for TENX?

Financial-distress signal — its Altman Z-Score of -1.83 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-61.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive clinical trial results for TNX-103, TNX-102, or TNX-201.
• Regulatory hurdles and delays in drug approval.
• Competition from larger pharmaceutical companies with greater resources.
• Limited financial resources and high cash burn rate.
• Patent expirations and generic competition.

What Are the Growth Opportunities for TENX?

• Expansion into New Therapeutic Areas: Tenax Therapeutics could leverage its expertise in cardiovascular and pulmonary diseases to expand into new therapeutic areas, such as chronic obstructive pulmonary disease (COPD) or heart failure. The global COPD market is projected to reach $16.8 billion by 2027, presenting a significant growth opportunity. This expansion would require additional research and development efforts, but could diversify the company's pipeline and reduce its reliance on pulmonary hypertension treatments. Timeline: 3-5 years.
• Geographic Expansion: Currently operating in the United States and Canada, Tenax Therapeutics could expand its geographic reach to Europe or Asia. The European market for pulmonary hypertension treatments is estimated at $1.5 billion, offering a substantial growth opportunity. This expansion would require navigating regulatory hurdles and establishing distribution networks in new markets. Timeline: 2-4 years.
• Strategic Partnerships and Collaborations: Tenax Therapeutics could pursue strategic partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its pipeline products. These partnerships could provide access to additional funding, expertise, and resources. This collaborative approach could enhance the company's ability to bring its therapies to market more quickly and efficiently. Timeline: Ongoing.
• Acquisition of Complementary Technologies or Assets: Tenax Therapeutics could acquire complementary technologies or assets to strengthen its pipeline and expand its capabilities. This could include acquiring companies with promising drug candidates in related therapeutic areas or technologies that enhance drug delivery or diagnostics. Such acquisitions could provide synergies and accelerate the company's growth. Timeline: 2-3 years.
• Orphan Drug Designation and Accelerated Approval Pathways: Tenax Therapeutics can leverage orphan drug designations and accelerated approval pathways for its therapies targeting rare diseases within the cardiovascular and pulmonary space. These regulatory mechanisms can expedite the drug development and approval process, providing a competitive advantage and faster market access. This strategy is particularly relevant for TNX-201 (imatinib) in treating pulmonary arterial hypertension. Timeline: Ongoing.

What Are TENX's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in cardiovascular and pulmonary diseases.
• Established relationships with key opinion leaders in the medical community.
• Focus on addressing unmet medical needs in specific disease subtypes.

What Does TENX Do?

Tenax Therapeutics, Inc., founded in 1967 and headquartered in Morrisville, North Carolina, is a specialty pharmaceutical company dedicated to identifying, developing, and commercializing innovative products for the treatment of cardiovascular and pulmonary diseases. Originally named Oxygen Biotherapeutics, Inc., the company rebranded to Tenax Therapeutics in September 2014, signaling a strategic shift in its focus and direction. The company's core mission is to address unmet medical needs in the treatment of pulmonary hypertension and related conditions. Tenax Therapeutics' pipeline includes several promising drug candidates. TNX-103 and TNX-102 (levosimendan) have completed Phase II clinical trials and are being developed for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF) and associated pulmonary hypertension. TNX-201 (imatinib), a tyrosine kinase inhibitor, is being developed for the treatment of pulmonary arterial hypertension (PAH). These therapies represent potential advancements in the treatment of these debilitating conditions. The company operates primarily in the United States and Canada, targeting specific patient populations with limited treatment options. Tenax Therapeutics aims to improve the lives of patients suffering from cardiovascular and pulmonary diseases through the development and commercialization of novel therapies. Their focus on pulmonary hypertension and related conditions positions them within a specialized segment of the pharmaceutical industry, where they strive to offer innovative solutions and address critical unmet medical needs.

What Products and Services Does TENX Offer?

• Develops TNX-103 for pulmonary hypertension associated with heart failure with preserved ejection fraction.
• Develops TNX-102 (levosimendan) for pulmonary hypertension associated with heart failure with preserved ejection fraction.
• Develops TNX-201 (imatinib) for pulmonary arterial hypertension.
• Identifies potential products for cardiovascular diseases.
• Identifies potential products for pulmonary diseases.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.

How Does TENX Make Money?

• Focuses on developing and commercializing pharmaceutical products.
• Generates revenue through the sale of approved therapies.
• Invests in research and development to expand its product pipeline.
• Seeks partnerships and collaborations to accelerate drug development and commercialization.

What Industry Does TENX Operate In?

Tenax Therapeutics operates within the biotechnology industry, specifically targeting the cardiovascular and pulmonary disease market. This market is characterized by significant unmet medical needs, particularly in the treatment of pulmonary hypertension and related conditions. The industry is highly competitive, with numerous pharmaceutical companies and biotechnology firms vying to develop innovative therapies. Key trends include the increasing prevalence of cardiovascular and pulmonary diseases, advancements in drug development technologies, and a growing emphasis on personalized medicine. Tenax Therapeutics' focus on specific disease subtypes and novel therapeutic approaches positions it within a niche segment of this dynamic landscape.

Who Are TENX's Key Customers?

• Patients with pulmonary hypertension associated with heart failure with preserved ejection fraction.
• Patients with pulmonary arterial hypertension.
• Hospitals and clinics that treat cardiovascular and pulmonary diseases.
• Physicians who prescribe medications for these conditions.

Return on equity for Tenax Therapeutics, Inc. stands at -61.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -53.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -92.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -67.6%, the inverse of the P/E and a quick read on earnings relative to price.

Tenax Therapeutics, Inc. (TENX) Valuation Context

Valued at $46.4M, TENX is classified as a micro-cap stock. Relative to its peer group, TENX's quantitative score of 28/100 is below the peer average of 77/100.

Company Profile

Tenax Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chapel Hill, US. The company is led by CEO Christopher T. Giordano. TENX has traded publicly since 1994.

Tenax Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.83 places it in the distress zone, a signal of elevated financial risk.

Tenax Therapeutics, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 50.0% above estimates on average.

Wall Street analysts project Tenax Therapeutics, Inc. revenue of about $4.2M for fiscal 2026, with EPS near $-1.45. The estimate reflects 9 contributing analysts.

TENX Financials

TENX Latest News

TENX Analyst Consensus

TENX MoonshotScore

What Investors Ask About Tenax Therapeutics, Inc. (TENX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources